Abstract
AbstractWe used cross-sectional surveys to compare the knowledge, attitudes, and decision regret of participants who had consented for genome sequencing (GS) for rare disease diagnosis in the 100,000 Genomes Project (100kGP) across two timepoints (at the time of consenting for GS (T1) and 12–18 months later (T2)). At T1, participants (n = 504) completed a survey that included measures of general knowledge of GS (“Knowledge of Genome Sequencing” (KOGS)), specific knowledge of GS and attitudes towards GS (“General attitudes” and “Specific attitudes”). At T2, participants (n = 296) completed these same assessments (apart from the specific knowledge scale) together with an assessment of decision regret towards GS (“Decisional Regret Scale”). At 12–18 months after consenting for GS, participants’ basic knowledge of GS had remained stable. General knowledge of GS varied across topics; concepts underlying more general information about genetics were better understood than the technical details of genomic testing. Attitudes towards GS at T2 were generally positive, and feelings towards GS (both positive and negative) remained unchanged. However, those who were more positive about the test at the outset had greater specific knowledge (as opposed to general knowledge) of GS. Finally, although the majority of participants indicated feeling little regret towards undergoing GS, those with low positive attitude and high negative attitude about GS at T1 reported greater decision regret at T2. Careful assessment of patient knowledge about and attitudes towards GS at the time of offering testing is crucial for supporting informed decision making and mitigating later regret.
Funder
DH | NIHR | Research for Patient Benefit Programme
Publisher
Springer Science and Business Media LLC
Subject
Genetics (clinical),Genetics
Reference28 articles.
1. Griffin BH, Chitty LS, Bitner-Glindzicz M. The 100 000 Genomes Project: What it means for paediatrics. Arch Dis Child Educ Pract Ed. 2017;102:105–7.
2. Genetic Alliance UK. Genome Sequencing and the NHS: The views of rare disease patients and carers. 2019. Published by: Genetic Alliance UK, London. https://www.geneticalliance.org.uk/wp-content/uploads/2019/07/Patient-Experience-100000GP.pdf.
3. Manickam K, McClain MR, Demmer LA, Biswas S, Kearney HM, Malinowski J, et al. Exome and genome sequencing for pediatric patients with congenital anomalies or intellectual disability: an evidence-based clinical guideline of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2021;23:2029–37.
4. Barwell J, Snape K, Wedderburn S. The new genomic medicine service and implications for patients. Clin Med. 2019;19:273–7.
5. Barwell JG, O’Sullivan RBG, Mansbridge LK, Lowry JM, Dorkins HR. Challenges in implementing genomic medicine: the 100,000 Genomes Project. Journal of Translational Genetics and Genomics. 2018;2:13.
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献